Incyte Atopic Dermatitis Cream Off To Good Start In US
Despite Warning On Topical JAK Inhibitor’s Label
Executive Summary
Certain launch challenges aside, the early commercial metrics and physician feedback look encouraging for Incyte's recently-approved topical JAK Opzelura for eczema.